Regenerative Treatments
for Ophthalmic Diseases

Neuroptika’s mission is to improve patients’ lives by developing novel regenerative therapies for ophthalmic diseases

NRO-1

A  POTENTIAL DISEASE MODIFYING TREATMENT

Neuroptika is leveraging insights into the relationship between nerve degeneration and ophthalmic diseases to develop transformative treatments.

NRO-1, Neuroptika's lead therapy, is a nerve regenerative therapeutic that can treat the underlying cause of degenerative ophthalmic diseases.

Corneal Nerve Degeneration

Dryeye_fnl.png

Retinal Ganglion Cell Degeneration

Glaucoma_eye_pressure_fnl.png
 

Axonal regeneration of corneal sensory nerves

2. ACCELERATES

Promotes_moonscape.png

Neurite elongation in trigeminal ganglion (peripheral) and retinal ganglion (central) cells

3. PROMOTES

Release_rocket_blu.png

1. RELEASES

Glial cell-derived neurotrophic factor (GDNF)

NRO-1 PROGRAMS

NRO-1 has successfully completed a Phase 1 study.  A Phase 2 study for dry eye disease is ongoing.

 

Functional Benefits of NRO-1

 
 

BACK TO TOP